This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Non-Interventional Study of Zoladex in Endometriosis

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: July 9, 2009
Last updated: February 19, 2014
Last verified: February 2014
This is a prospective, open label NIS, which is to assess the efficacy of Zoladex in adjuvant setting after operation in moderate to severe endometriosis patients.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Non-interventional Study of Postoperative Treatment With Goserelin Acetate (Zoladex) in Moderate to Severe Endometriosis Patient

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Symptom recurrence rate and total recurrence rate [ Time Frame: 18 months ]

Secondary Outcome Measures:
  • Pregnancy rate [ Time Frame: 18 months ]
  • Zoladex administration time [ Time Frame: 6 months ]
  • Add-back therapy information [ Time Frame: 18 months ]

Enrollment: 408
Study Start Date: July 2009
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Study Population Description: Patient with advanced endometriosis confirmed histological (r-AFS score III-IV) with conservative laparoscopy or laparotomy has the indication of Zoladex and has already been prescribed Zoladex according to physician's judgment, irrespective of the inclusion in the study

Inclusion Criteria:

  • Advanced endometriosis confirmed histologically (r-AFS score III-IV) with conservative laparoscopy or laparotomy.
  • Patient who has the indication of Zoladex and has been prescribed Zoladex according to physician's judgement, irrespective of the inclusion in the study.
  • Patient has been already prescribed Zoladex within 1 month after operation.

Exclusion Criteria:

  • Have used hormone treatment prior to 3 months of recruitment.
  • Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
  • Previous enrolment in the present study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00938496

China, Anhui
Research Site
Hefei, Anhui, China
China, Beijing
Research Site
Beijing, Beijing, China
China, Guangdong
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
China, Heilongjiang
Research Site
Harbin, Heilongjiang, China
China, Hunan
Research Site
Changsha, Hunan, China
China, Liaoning
Research Site
Shenyang, Liaoning, China
China, Shanghai
Research Site
Shanghai, Shanghai, China
China, Shanxi
Research Site
Xi'an, Shanxi, China
China, Sichuan
Research Site
Chengdu, Sichuan, China
China, Zhejiang
Research Site
Hangzhou, Zhejiang, China
Sponsors and Collaborators
Principal Investigator: Zhou Yingfang Peking University First Hospital
  More Information

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT00938496     History of Changes
Other Study ID Numbers: NIS-OCN-ZOL-2009/1
Study First Received: July 9, 2009
Last Updated: February 19, 2014

Additional relevant MeSH terms:
Genital Diseases, Female
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on September 21, 2017